Acute Myeloid Leukemia (AML) Articles


  • TAT-10: Efficacy of Actinium-225-labeled Anti-CD33 Antibody in Acute Myeloid Leukemia Correlates with Peripheral Blast Count

    Kanazawa, Japan ( This study was conducted in two phases. Phase one had 18 relapsed and refractory acute myeloid leukemia (AML) patients. Patients were treated with a single infusion of Actimab-A, the company’s name for Ac-225 conjugated to the anti-CD33 monoclonal antibody lintuzumab. Doses ranged from 18.5 to 148 kBq/kg and post analysis determined a maximum dose of 111 kBq/kg. In the second trial (18 newly diagnosed patients), were treated with two equal doses at 14 days and 21 days. Total doses ranged from 37 to 148 kB/kq.
    Published June 21, 2017
email news signup